Sage shares cut in half after postpartum drug approval. Here’s what happened.

The Cambridge drugmaker saw its market value drop by about $1 billion in the first minutes of trading Monday, following a partial approval of a new depression drug late Friday. Cambridge-based Sage had applied to market the depression drug, zuranolone, as a treatment for both major depressive disorder (MDD) and postpartum depression (PPD). The U.S.…

Read More

Postpartum depression drug developed by Sage, Biogen approved by FDA

A new depression drug has received the green light from the U.S. Food and Drug Administration after years of development by two Cambridge drugmakers. Zuranolone, a new drug co-developed by Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics Inc. (Nasdaq: SAGE), scored an FDA approval late Friday — but the approval was only for postpartum depression,…

Read More